Brief: Bridgebio Pharma Says Intends To Initiate Registrational Clinical Study Of Encaleret In 2026
06/09/2025 19:32
Sept 6 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO PHARMA - INTENDS TO INITIATE REGISTRATIONAL CLINICAL STUDY OF ENCALERET IN 2026 ENCALERET WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED OVER STUDY PERIOD PHASE 2 STUDY EVALUATED ENCALERET'S EFFECTS ON CALCIUM HANDLING Source text: ID:nGNX4kw9bq Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels